Combined Weekly Topotecan and Biweekly Bevacizumab in Women With Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer: Results of a Phase 2 Study

A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum-resistant ovarian, peritoneal, or fallopian tube cancer (OC). Patients were treated with bevacizumab 10 mg/kg on days 1 and 15 and...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer Vol. 117; no. 16; pp. 3731 - 3740
Main Authors:	MCGONIGLE, Kathryn F, MUNTZ, Howard G, VUKY, Jacqueline, PALEY, Pamela J, VELJOVICH, Dan S, GREER, BenjaminE, GOFF, BarbaraA, GRAY, Heidi J, MALPASS, Thomas W
Format:	Journal Article
Language:	English
Published:	Hoboken, NJ Wiley-Blackwell 15-08-2011
Subjects:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Drug Administration Schedule Drug Resistance, Neoplasm Fallopian Tube Neoplasms - drug therapy Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Ovarian Neoplasms - drug therapy Peritoneal Neoplasms - drug therapy Platinum Compounds - pharmacology Topotecan - administration & dosage Tumors Antineoplastic agent Carcinoma Ovary cancer Fallopian tube cancer Administration schedule Monoclonal antibody angiogenesis inhibitors primary peritoneal carcinoma Bevacizumab Isomerases Cancerology Platinum Phase II trial Primary Adult Female Antiangiogenic agent Woman Topoisomerase I inhibitor Fallopian tube pathology Camptothecin derivatives Human Enzyme ovarian cancer DNA topoisomerase Enzyme inhibitor Topotecan Malignant tumor Female genital diseases Resistance Ovarian diseases Chemotherapy Treatment Vascular endothelium growth factor Peritoneal cancer Cancer Peritoneum
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A phase 2 trial was conducted to determine the toxicity and efficacy of combined weekly topotecan and biweekly bevacizumab in patients with primary or secondary platinum-resistant ovarian, peritoneal, or fallopian tube cancer (OC). Patients were treated with bevacizumab 10 mg/kg on days 1 and 15 and topotecan 4 mg/m(2) on days 1, 8, and 15 of a 28-day cycle until progressive disease (PD) or excessive toxicity. The primary endpoint was progression-free survival (PFS); secondary objectives included overall survival (OS), objective response, and toxicity. Patients (N = 40) received a median of 8 treatment cycles. Toxicity was generally mild or moderate, with neutropenia (18%), hypertension (20%), gastrointestinal toxicity (18%), pain (13%), metabolic toxicity (15%), bowel obstruction (10%), and cardiotoxicity (8%) being the most common grade 3 and 4 adverse events. No bowel perforations, febrile neutropenia, or treatment-related deaths occurred. Median PFS and OS were 7.8 (95% confidence interval [CI], 3.0-9.4) and 16.6 months (95% CI, 12.8-22.9), with 22 (55%) patients progression-free for ≥6 months. Ten (25%) patients had partial response (PR), 14 (35%) had stable disease (SD), and 16 (40%) had PD. Patients treated with 2 prior regimens received greater benefit than patients treated with 1: PR/SD, 78.9% versus 42.9% (P = .03); median PFS, 10.9 versus 2.8 months (P = .08); median OS, 22.9 versus 12.8 months (P = .02). A weekly topotecan and biweekly bevacizumab combination demonstrates acceptable toxicity and encouraging efficacy in patients with platinum-resistant OC; further study is warranted.
ISSN:	0008-543X 1097-0142
DOI:	10.1002/cncr.25967